29-Jan-2026
BOCOM International Holdings Company Sticks to Their Buy Rating for HUTCHMED (China) (HCM)
TipRanks (Thu, 29-Jan 2:38 AM ET)
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
Globe Newswire (Tue, 13-Jan 11:00 PM ET)
Globe Newswire (Tue, 6-Jan 7:00 PM ET)
Globe Newswire (Sun, 4-Jan 7:00 PM ET)
Globe Newswire (Tue, 30-Dec 5:00 AM ET)
Globe Newswire (Mon, 29-Dec 3:35 AM ET)
Globe Newswire (Tue, 16-Dec 7:00 PM ET)
Globe Newswire (Sun, 7-Dec 7:00 PM ET)
Globe Newswire (Wed, 26-Nov 7:00 PM ET)
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Globe Newswire (Wed, 5-Nov 8:35 AM ET)
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Hutchmed (China) Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol HCM.
As of January 29, 2026, HCM stock price climbed to $15.25 with 13,308 million shares trading.
HCM has a beta of 0.35, meaning it tends to be less sensitive to market movements. HCM has a correlation of 0.02 to the broad based SPY ETF.
HCM has a market cap of $2.62 billion. This is considered a Mid Cap stock.
In the last 3 years, HCM traded as high as $21.92 and as low as $10.68.
The top ETF exchange traded funds that HCM belongs to (by Net Assets): SPDW, CANC, DFEM, NSI, DFAX.
HCM has underperformed the market in the last year with a price return of +13.0% while the SPY ETF gained +16.0%. However, in the short term, HCM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +4.0% vs +1.3% return in SPY. But in the last 2 weeks, HCM shares have been beat by the market, returning -0.3% compared to an SPY return of +0.5%.
HCM support price is $14.86 and resistance is $15.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HCM shares will trade within this expected range on the day.